Determining the value of surgical therapies for basal cell carcinoma

Archives of Dermatology

Volumn 142, Issue 2, 2006, Pages 231-232

  Chren, Mary Margaret ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASAL CELL CARCINOMA; CANCER SURGERY; CHEMOSURGERY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; EDITORIAL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGH RISK BEHAVIOR; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REIMBURSEMENT; SKIN CANCER; TREATMENT OUTCOME; TUMOR RECURRENCE;

CARCINOMA, BASAL CELL; COSTS AND COST ANALYSIS; FOLLOW-UP STUDIES; HUMANS; MOHS SURGERY; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 33244469732     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.142.2.231     Document Type: Editorial

References (17)

1. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol. 1999;135:1177-1183.
2. Bath FJ, Bong J, Perkins W, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2003;(2):CD003412.
3. McGovern TW, Leffell DJ. Mohs surgery: the informed view. Arch Dermatol. 1999;135:1255-1259.
4. Smeets NW, Krekels GA, Ostertag JU, et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face. Lancet. 2004;364:1766-1772.
5. Essers BAB, Dirksen CD, Nieman FHM, et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Arch Dermatol. 2006;142:187-194.
6. Chren MM, Sahay AP, Sands LP, et al. Variation in care for nonmelanoma skin cancer in a private practice and a veterans affairs clinic. Med Care. 2004;42:1019-1026.
7. O'Brien BJ, Heyland D, Richardson WS, Levine M, Drummond MF; Evidence-Based Medicine Working Group. Users' guides to the medical literature, XIII: how to use an article on economic analysis of clinical practice, B. JAMA. 1997;277:1802-1806.
8. Drummond MF, Richardson WS, O'Brien BJ, Levine M, Heyland D; Evidence-Based Medicine Working Group. Users' guides to the medical literature, XIII: how to use an article on economic analysis of clinical practice, A. JAMA. 1997;277:1552-1557.
9. Cook J, Zitelli JA. Mohs micrographic surgery: a cost analysis. J Am Acad Dermatol. 1998;39:698-703.
10. Bialy TL, Whalen J, Veledar E, et al. Mohs micrographic surgery vs traditional surgical excision: a cost comparison analysis. Arch Dermatol. 2004;140:736-742.
11. Otley CC. Mohs' micrographic surgery for basal-cell carcinoma of the face. Lancet. 2005;365:1226-1227.
12. Haynes B. Can it work? does it work? is it worth it? the testing of healthcare interventions is evolving. BMJ. 1999;319:652-653.
13. Chren MM, Weinstock MA. Conceptual issues in measuring the burden of skin diseases. J Investig Dermatol Symp Proc. 2004;9:97-100.
14. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27:S217-S232.
15. Chen JG, Fleischer AB Jr, Smith ED, et al. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg. 2001;27:1035-1038.
16. Joseph AK, Mark TL, Mueller C. The period prevalence and costs of treating nonmelanoma skin cancers in patients over 65 years of age covered by medicare. Dermatol Surg. 2001;27:955-959.
17. Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003; 48:425-429.